GLPwatch
The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
NCT03426085 · Unknown status
Last updated 2026-05-28This clinical trial tests whether the medication liraglutide improves sweat gland function and reduces inflammation in adults with type 2 diabetes who have nerve-related complications.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, triple-blind prevention study
Participants 44 people Planned (estimated).
Who can join Ages 18–80 · all sexes
Timeline Started 2016-05 · est. completion 2020-08
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT03426085 ↗
Description as written by the study sponsor.
The purpose of this study is to conduct an interventional, one year, randomized, double blind, placebo-controlled trial with Liraglutide in patients with type 2 diabetes (diabetes duration of \>6 months and \<10 years, HbA1c \<10%) to evaluate its effects on the peripheral autonomic nervous system, as well as inflammatory markers, and measures of oxidative and nitrosative stress.
Treatments tested
- Liraglutide 6 mg Solution for Injection Drug
- Placebo Other
| Main thing measured | Sudomotor Function |
|---|---|
| Sponsor | Eastern Virginia Medical School |
| Conditions studied | Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03426085 ↗